Biochemical markers in multiple myeloma: a multivariate analysis

  title={Biochemical markers in multiple myeloma: a multivariate analysis},
  author={Bengt Simonsson and C K{\"a}llander and Gunilla Brenning and Andreas Killander and J. Simon Gronowitz and Reinhold Bergstr{\"o}m and Anders {\AA}hre},
  journal={British Journal of Haematology},
Summary. The analysis of individual biochemical and clinical variables in 121 patients with multiple myeloma showed that serum β2‐microglobulin (S‐β2m) had the most significant relation to survival. Other variables such as serum thymidine kinase (S‐TK), serum lactate dehydrogenase (S‐LDH), Screatinine, haemoglobin (Hb), ESR, S‐albumin, age and clinical stage were also significant. No such relationship was found with M‐component, presence of light chains in urine, type of secreted immunoglobulin… 

C-reactive protein (CRP) levels do not reflect disease status in patients with multiple myeloma.

It is concluded that CRP measurements are not valuable as a monitor of disease activity in patients with myeloma.

Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma.

The International Staging System (ISS) is currently in use; it is highly prognostic but presents some limitations, and it is suggested that the ISS prognostic potential could be improved with the addition of sFLCR and eventually LDH.

Prognostic factors affecting the survival of patients with multiple myeloma. A retrospective analysis of 86 patients.

A strong prediction of survival was found by grouping the serum creatinine and haemoglobin levels of patients at presentation, and age, sex, Durie and Salmon staging, lytic lesions, serum immunoglobulin concentration, urine Bence Jones protein, and type of chemotherapy given were not significantly associated with survival.

Lymphoid subsets and prognostic factors in multiple myeloma

Multivariate analysis showed that the number of CD4 cells add independent prognostic information to other well‐established tests for the assessment of disease outcome in patients with multiple myeloma.

Ki-67 Proliferation Index: Correlation With Prognostic Parameters and Outcome in Multiple Myeloma

Ki-67 determination during routine pathological analysis of bone marrow in newly diagnosed multiple myeloma patients could provide useful information about the proliferative activity and prognosis of the disease.

A new prognostic system for multiple myeloma based on easily available parameters

The prognostic significance of different presenting features in 180 patients with multiple myeloma from a single institution was analysed and only the latter one showed prognostic validity.

Clinical and biological significance of serum tumor markers in adult T-cell leukemia.

Four serum tumor markers at diagnosis of ATL showed a correlation with among leukocyte count, absolute number of abnormal lymphocytes with polymorphic nuclei, platelet count, serum calcium and the length of survival after the initial diagnosis.

Long‐term prognostic value of serum β2 microglobulin in myelomatosis

Analysis of 1014 patients confirmed the value of presentation sβ2m of predicting survival in the short term but showed that predictive value was lost for subsequent survival in those patients who had survived for at least 2 years.



Prognostic value of serum lactic dehydrogenase (S‐LDH) in multiple myeloma

Serum lactic dehydrogenase at diagnosis has prognostic information in multiple myeloma and in discriminant analysis of pretreatment S‐LDH levels in relation to survival, the best discrimination level was 7·0 μkat l‐1.

Prognostic factors and staging in multiple myeloma: a reappraisal.

S beta 2M and the serum albumin level, variables not included in the three MSS, were better indicators than the classical DS MSS and could be combined simply to give a very powerful system of stratification.

Pretreatment serum β2‐microglobulin in multiple myeloma

It is concluded that pretreatment S‐β2 microglobulin is a useful marker for predicting survival in multiple myeloma.

The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.

Serum beta 2 microglobulin levels, uncorrected for serum creatinine, were found to be the single most powerful prognostic variable available at presentation and the addition of haemoglobin levels could improve upon this.

A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients.

The comparison of the duration of survival between the three groups of staged patients confirmed the high reliability of the present staging system, and bivariate correlation and multivariate regression analyses showed that the survival could be accurately predicted in IgG and pure Bence Jones myeloma patients.

Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring.

Analysis of the influence of a rising serum creatinine on the serum beta 2-m indicates that beta 2 -m production is excessive in advanced disease with or without renal failure.

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

Initial staging can be quantitatively related to followup using tumor cell mass changes calculated from changes in M‐component production, and should lead to improved study design and analysis in large clinical trials of therapy for multiple myeloma.

Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma

S‐TK correlated with the haemoglobin level but did not correlate with sex, age, erythrocyte sedimentation rate, nor with the serum concentrations of creatinine, β2‐microglobulin, Ca or M‐component.

Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma.

It is concluded that the pretreatment labeling index provides helpful prognostic information in addition to tumor mass staging in patients with multiple myeloma.

Beta2 microglobulin in multiple myeloma

Serum beta2 microglobulin levels were evaluated before and during chemotherapy in 97 previously untreated patients with multiple myeloma and a pretreatment B2M value greater than 6 mg/L correlated with a low response rate and was the most important variable that predicted a short survival time.